Related Experiment Videos
[Detection of activated platelets by flow cytometry]
While bleeding time and platelet aggregometry are the two standard clinical tests of platelet function, an increasing number of flow cytometric studies using activation-dependent monoclonal antibodies have been reported recently. Those include an IgM antibody, PAC-1, which binds to the fibrinogen binding site exposed by a conformational change in the GPIIb-IIIa complex of activated platelets. In our study, platelets in whole blood bound to PAC-1 when activated by a wide range of ADP concentrations. ADP-induced PAC-1 binding to platelets was suppressed in individuals who had taken an oral antiplatelet drug, ticlopidine. Whole blood flow cytometry have advantages such as minimal artifact and smaller sample volume. Platelet activation and its suppression by antiplatelet therapy may be evaluated by using ADP-induced PAC-1 binding in many clinical settings where platelet hyperreactivity and/or circulating activated platelets play a role.
While bleeding time and platelet aggregometry are the two standard clinical tests of platelet function, an increasing number of flow cytometric studies using activation-dependent monoclonal antibodies have been reported recently. Those include an IgM antibody, PAC-1, which binds to the fibrinogen binding site exposed by a conformational change in the GPIIb-IIIa complex of activated platelets. In our study, platelets in whole blood bound to PAC-1 when activated by a wide range of ADP concentrations. ADP-induced PAC-1 binding to platelets was suppressed in individuals who had taken an oral antiplatelet drug, ticlopidine. Whole blood flow cytometry have advantages such as minimal artifact and smaller sample volume. Platelet activation and its suppression by antiplatelet therapy may be evaluated by using ADP-induced PAC-1 binding in many clinical settings where platelet hyperreactivity and/or circulating activated platelets play a role.